ClinicalTrials.gg
CompletedNCT02259010Updated Sep 20, 2019Results posted

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

A Phase 1 interventional study of Alisertib and Itraconazole in Advanced Solid Tumors and Relapsed/Refractory Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-20.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.

Enrollment
19th of 23
24 · median 36
Started
2014
with 4 others
Phase 1
12 of 26
none open now
Registered
19th of 26
by date

Among the 26 studies in Lymphoma by Takeda, this one is the 19th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2014, is one of 12 in phase 1, and was the 19th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lymphoma by Takeda, or all of them as a file.
02

Study summary

This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.

Read the detailed description

The drug being tested in this study is called alisertib. Alisertib is being tested in adult participants with advanced solid tumors or relapsed refactory lymphoma. The study will look at the effect of the pharmacokinetics (how the drug moves through the body) of alisertib in the presence and absence of itraconazole.

This is an open label study. Participants will receive:

  • Alisertib tablets 30 mg in Part A and 50 mg in Part B
  • Itraconazole oral solution 200 mg in Part A

Participation in Part A is approximately 25 days. Part B participation is repeating 21-day cycles. The maximum duration of treatment with alisertib will be 12 months (approximately 16 cycles) unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months.

This multi-center study will take place in the United States.

03

Conditions studied

  • Advanced Solid Tumors
  • Relapsed/Refractory Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants 18 years of age or older.
  2. Participants with histologic or cytologic diagnosis of advanced or solid tumors or lymphomas for which no curative or life-prolonging therapies exist.
  3. (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria

  1. Systemic treatment with moderate or strong inhibitors or inducers must be discontinued at least 14 days before the first dose of alisertib, and the use of these agents is not permitted during the study (except for the protocol-specified administration of itraconazole).
  2. Known gastrointestinal (GI) abnormality (including recurrent nausea or vomiting) or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib.
  3. Known or intolerance to itraconazole or similar class agents.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg

    All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).

    Drug: Alisertib · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  2. AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  3. AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

Secondary outcomes

  1. CL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  2. Tmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  3. Terminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  4. Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  5. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  6. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A

    Time frame: Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)

  8. Number of Participants With Abnormal Laboratory Values Reported as AEs

    Standard safety laboratory tests included Chemistry and Hematology. Abnormal laboratory values that led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be a clinically significant change from baseline were reported as AEs.

    Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)

  9. Number of Participants With Clinically Significant Change in Weight Reported as AEs

    Change relative to baseline in participant's weight measured throughout study.

    Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)

  10. Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs

    Vital signs will include body temperature (oral), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).

    Time frame: First dose of study drug to 30 days after the last dose of study drug (up to 12 months)

07

Results

Posted Sep 20, 2019

Participant flow

Participants took part in the study at 4 investigative sites in the United States from 22 October 2014 to 21 October 2016. Data cutoff for the primary analysis was 27 March 2015.

Participant flow — Overall Study
MilestonePart A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Started24
Completed19
Not completed5
Withdrew: Didn't completed dosing; pk assessment5

Outcome measures

PrimaryCmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Mean · nmol/L
Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
nmol/LAlisertib Without ItraconazoleAlisertib With Itraconazole
Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A1060.3 ± 403.901002.8 ± 263.81
Statistical analysis
  • Alisertib Without Itraconazole vs Alisertib With Itraconazole · Least squares mean ratio: 0.98 · 90% CI 0.82 to 1.19Estimates were obtained using a mixed effects model of log (PK parameter) with fixed terms for the itraconazole effect and random terms for participant within period.
PrimaryAUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Mean · hr*nmol/L
AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
hr*nmol/LAlisertib Without ItraconazoleAlisertib With Itraconazole
AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib in Presence and Absence of Itraconazole in Part A15541.6 ± 9119.5220219.5 ± 9930.93
Statistical analysis
  • Alisertib Without Itraconazole vs Alisertib With Itraconazole · Least squares mean ratio: 1.35 · 90% CI 1.02 to 1.79Estimates were obtained using a mixed effects model of log (PK parameter) with fixed terms for the itraconazole effect and random terms for participant within period.
PrimaryAUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Mean · hr*nmol/L
AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A
hr*nmol/LAlisertib Without ItraconazoleAlisertib With Itraconazole
AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib in Presence and Absence of Itraconazole in Part A16804.6 ± 9232.8723488.7 ± 13262.31
Statistical analysis
  • Alisertib Without Itraconazole vs Alisertib With Itraconazole · Least squares mean ratio: 1.39 · 90% CI 0.99 to 1.95Estimates were obtained using a mixed effects model of log (PK parameter) with fixed terms for the itraconazole effect and random terms for participant within period.
SecondaryCL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Mean · L/hr
CL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A
L/hrAlisertib Without ItraconazoleAlisertib With Itraconazole
CL/F: Oral Clearance of Alisertib in Presence and Absence of Itraconazole in Part A4.416 ± 2.40073.177 ± 1.5765
SecondaryTmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Median · hr
Tmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A
hrAlisertib Without ItraconazoleAlisertib With Itraconazole
Tmax: Time to Reach Maximum Plasma Concentration of Alisertib in Presence and Absence of Itraconazole in Part A2.920 ± 2.37102.920 ± 2.0244
SecondaryTerminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Mean · hr
Terminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A
hrAlisertib Without ItraconazoleAlisertib With Itraconazole
Terminal Phase Elimination Half-Life of Alisertib in Presence and Absence of Itraconazole in Part A22.55 ± 10.31625.37 ± 9.215
SecondaryCmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Mean · nmol/L
Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
nmol/LAlisertib Without ItraconazoleAlisertib With Itraconazole
Metabolite 1 (M1)409.4 ± 479.92450.0 ± 664.65
Metabolite 2 (M2)114.0 ± 52.71103.5 ± 99.28
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Median · hr
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
hrAlisertib Without ItraconazoleAlisertib With Itraconazole
Metabolite 1 (M1)3.090 (1.00 to 23.10)3.800 (1.98 to 10.00)
Metabolite 2 (M2)9.360 (2.95 to 47.70)23.600 (5.73 to 95.30)
SecondaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
Time frame:
Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib without itraconazole arm; Day 10 pre-dose and at multiple time points (up to 96 hours) post-dose in Cycle 1 for alisertib with itraconazole arm
Reported as:
Mean · hr*nmol/L
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2 in Presence and Absence of Itraconazole in Part A
hr*nmol/LAlisertib Without ItraconazoleAlisertib With Itraconazole
Metabolite 1 (M1)10550.8 ± 17276.3815776.1 ± 29461.34
Metabolite 2 (M2)5880.6 ± 3404.275081.6 ± 3334.41
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
AEs24
SAEs12
SecondaryNumber of Participants With Abnormal Laboratory Values Reported as AEs

Standard safety laboratory tests included Chemistry and Hematology. Abnormal laboratory values that led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be a clinically significant change from baseline were reported as AEs.

Time frame:
First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Values Reported as AEs
ParticipantsPart A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Hypokalemia3
Elevated blood creatinine3
Increased international normalized ratio2
Hypercalcemia1
Hypomagnesemia1
Hypoalbuminemia1
Decreased blood potassium1
Decreased blood sodium1
Elevated blood alkaline phosphatase1
Anemia5
Neutropenia4
Leukopenia2
Thrombocytopenia2
Decreased lymphocyte count2
Decreased white blood cell count1
Decreased platelet count1
SecondaryNumber of Participants With Clinically Significant Change in Weight Reported as AEs

Change relative to baseline in participant's weight measured throughout study.

Time frame:
First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Weight Reported as AEs
ParticipantsPart A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Number of Participants With Clinically Significant Change in Weight Reported as AEs2
SecondaryNumber of Participants With Clinically Significant Change in Vital Sign Reported as AEs

Vital signs will include body temperature (oral), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).

Time frame:
First dose of study drug to 30 days after the last dose of study drug (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Vital Sign Reported as AEs
ParticipantsAlisertib Without Itraconazole
Pyrexia3
Palpitations2
Tachycardia1

Adverse events

Collected over First dose of study drug up to 30 days after the last dose of study drug (up to 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg1/24 (4.2%)12/24 (50%)24/24 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPart A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
AnaemiaBlood and lymphatic system disorders2/24
Abdominal painGastrointestinal disorders1/24
ConstipationGastrointestinal disorders1/24
Intestinal obstructionGastrointestinal disorders1/24
VomitingGastrointestinal disorders1/24
Gastrointestinal haemorrhageGastrointestinal disorders1/24
MelaenaGastrointestinal disorders1/24
Upper gastrointestinal haemorrhageGastrointestinal disorders1/24
CellulitisInfections and infestations1/24
Herpes zoster disseminatedInfections and infestations1/24
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPart A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
NauseaGastrointestinal disorders11/24
DiarrhoeaGastrointestinal disorders10/24
FatigueGeneral disorders9/24
VomitingGastrointestinal disorders8/24
AlopeciaSkin and subcutaneous tissue disorders8/24
StomatitisGastrointestinal disorders7/24
HeadacheNervous system disorders7/24
ConstipationGastrointestinal disorders6/24
Oedema peripheralGeneral disorders6/24
Decreased appetiteMetabolism and nutrition disorders6/24

Baseline characteristics

Safety Population is defined as all participants who received at least 1 dose of any study drug and was used for all safety analyses.

Age, Continuous
Age, Continuous(years)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Mean61.0 ± 9.52
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Female13
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Hispanic or Latino1
Not Hispanic or Latino20
Not Reported3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
White20
Black or African American2
Asian1
Other1
Region of Enrollment
Region of Enrollment(Participants)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
United States24
Height
Height(cm)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Mean168.3 ± 8.99
Weight
Weight(kg)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Mean85.55 ± 25.641
Body Surface Area
Body Surface Area(m^2)Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg
Mean1.983 ± 0.3024
08

Study locations

4 sites
  • Saint Louis, Missouri, United States
  • Oklahoma City, Oklahoma, United States
  • Germantown, Tennessee, United States
  • Dallas, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Mar 2015, 5 months.

Results were first posted in Sep 2019, 4 years 5 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 5 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2014
First posted
Oct 8, 2014
StartActual
Oct 22, 2014
Primary completionActual
Mar 27, 2015
CompletionActual
Oct 21, 2016
Results first posted
Sep 20, 2019
Last update
Sep 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02259010
Responsible party
Sponsor
First posted
Oct 8, 2014
Start date
Oct 22, 2014
Primary completion
Mar 27, 2015
Completion
Oct 21, 2016
Results posted
Sep 20, 2019
Last update
Sep 20, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion